MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.100
+0.050
+4.76%
Closed 16:00 05/13 EDT
OPEN
1.080
PREV CLOSE
1.050
HIGH
1.110
LOW
1.040
VOLUME
47.92K
TURNOVER
35.84K
52 WEEK HIGH
1.990
52 WEEK LOW
1.000
MARKET CAP
65.28M
P/E (TTM)
-1.9643
1D
5D
1M
3M
1Y
5Y
Akari Therapeutics net loss of $17.4M
Akari Therapeutics press release (NASDAQ:AKTX): FY Net loss of $17.4M. Cash of approximately $9.4M. “During the last twelve months, Akari has advanced nomacopan pre-clinical and clinical development programs, including three
Seekingalpha · 1h ago
BRIEF-Akari Therapeutics Reports Full Year 2021 Financial Results And Highlights Clinical Progress
reuters.com · 1h ago
BRIEF-Akari Therapeutics Announces Publication Of Phase Ii Data Of Investigational Nomacopan For The Treatment Of Bullous Pemphigoid (BP) In Jama Dermatology
reuters.com · 6d ago
Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology
Patients received subcutaneous nomacopan (30 mg once daily) with lesional mometasone from Day 1 to 21 of treatment and nomacopan only from Day 21 to Day 42Seven of nine patients responded to nomacopan with three, regarded as complete responders, showing >8...
GlobeNewswire · 6d ago
BRIEF-Akari Presents Results From Two Preclinical Development Programs Of Long-Acting Pas-Nomacopan
reuters.com · 05/09 11:37
Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)
Preclinical data show investigational intravitreal long-acting PASylated-nomacopan (PAS-nomacopan) effective in inhibiting choroidal neovascularization (CNV), which is a risk related to certain complement inhibitors that otherwise appear to be effective in...
GlobeNewswire · 05/09 11:00
Notable earnings before Tuesday's open
AKTX,BMI,CFG,FITB,HAL,HAS,IRDM,JNJ,LGMK,LMT,MAN,PLD,SBNY,SI,TFC,TRV For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 04/18 14:45
Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
NEW YORK and LONDON, March 21, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leuk...
GlobeNewswire · 03/21 12:00
More
No Data
Learn about the latest financial forecast of AKTX. Analyze the recent business situations of Akari Therapeutics Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AKTX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
High5.00
Average5.00
Low5.00
Current 1.100
EPS
Actual
Estimate
-0.46-0.35-0.23-0.12
Q4 2020
    0
Q1 2021
  • 0
Q2 2021
Q3 2021
Q3 2018
Institutional Holdings
Institutions: 20
Institutional Holdings: 2.50M
% Owned: 4.22%
Shares Outstanding: 59.35M
TypeInstitutionsShares
Increased
2
132.06K
New
0
0
Decreased
0
0
Sold Out
1
1.62K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+4.51%
Pharmaceuticals & Medical Research
+1.39%
Key Executives
Chairman/Executive Director
Ray Prudo
President/Chief Executive Officer/Director
Rachelle Jacques
Chief Financial Officer
Torsten Hombeck
Chief Operating Officer/Director
Clive Richardson
Director
Michael Grissinger
Independent Director
David Byrne
Independent Director
Peter Feldschreiber
Independent Director
James Hill
Independent Director
Stuart Ungar
Independent Director
Donald Williams
No Data
No Data
About AKTX
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company. The Company is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid or leukotriene system and the bioamine system for the treatment of rare and orphan diseases. Its lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4 (LTB4). It inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement. It inhibits LTB4 by capturing the fatty acid within the body of the nomacopan protein. The anaphylatoxin (C5a) and the membrane attack complex (MAC) cause and maintain a proinflammatory and prothrombotic state. LTB4 also activates cells via two separate GPCRs and can independently cause and maintain a proinflammatory state.

Webull offers kinds of Akari Therapeutics PLC (ADR) stock information, including NASDAQ:AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.